Russia's Natsimbio and R-Pharm partner on HIV drugs

Russian R-Pharm Group together with Natsimbio, the country’s leading producer of vaccines, have reached an agreement on the establishment a joint venture for the production and sales drugs against HIV in Russia, reports The Pharma Letter’s local correspondent.

The first production of the joint venture will be released before the end of the current year. Alexey Ordzhonikidze, R-Pharm's vice president, said that the joint venture with Natsimbio will unite all the existing anti-HIV developments of both companies and will also focus on the development of new products.

In the case of Natsimbio, according to the company, it currently does not have its own production of anti-HIV drugs. At the same time the portfolio of R-Pharm, according to its representative, includes 14 of its own generics at various stages of sales, as well as three drugs that the company produces on contract at its plant in the Yaroslavl region.